{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:40:10Z","timestamp":1737445210743,"version":"3.33.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T00:00:00Z","timestamp":1190937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2007,11,15]]},"DOI":"10.1007\/s12028-007-0070-4","type":"journal-article","created":{"date-parts":[[2007,9,27]],"date-time":"2007-09-27T15:58:23Z","timestamp":1190908703000},"page":"194-202","source":"Crossref","is-referenced-by-count":9,"title":["High-dose Bosentan in the Prevention and Treatment of Subarachnoid Hemorrhage-induced Cerebral Vasospasm: An Open-label Feasibility Study"],"prefix":"10.1007","volume":"7","author":[{"given":"Raul G.","family":"Nogueira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Bodock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter J.","family":"Koroshetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet A.","family":"Topcuoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob S.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Ogilvy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny C.","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando S.","family":"Buonanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,28]]},"reference":[{"key":"70_CR1","unstructured":"Warlow CD, Dennis MS, Van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, Wardlaw JM. Specific treatment of aneurysmal subarachnoid haemorrhage. In: Stroke - A practical guide to management, 2nd ed. Blackwell Science Inc; February 2001."},{"key":"70_CR2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/WNL.50.5.1413","volume":"50","author":"SC Johnston","year":"1998","unstructured":"Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology 1998;50:1413\u20138.","journal-title":"Neurology"},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1212\/WNL.33.4.424","volume":"33","author":"JP Kistler","year":"1983","unstructured":"Kistler JP, Crowell RM, Davis KR, et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. Neurology 1983;33:424\u201336.","journal-title":"Neurology"},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/WNL.37.10.1586","volume":"37","author":"HP Adams Jr.","year":"1987","unstructured":"Adams HP Jr., Kassell NF, Torner JC, Haley EC Jr. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987;37:1586\u201391.","journal-title":"Neurology"},{"key":"70_CR5","first-page":"249","volume":"48","author":"MM Treggiari-Venzi","year":"2001","unstructured":"Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery 2001;48:249\u201361; discussion 261\u20132.","journal-title":"Neurosurgery"},{"key":"70_CR6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00006123-199810000-00083","volume":"43","author":"M Zimmermann","year":"1998","unstructured":"Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 1998;43:863\u201375; discussion 875\u20136.","journal-title":"Neurosurgery"},{"key":"70_CR7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/00006123-200212000-00002","volume":"51","author":"M Chow","year":"2002","unstructured":"Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 2002;51:1333\u201341; discussion 1342.","journal-title":"Neurosurgery"},{"key":"70_CR8","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1161\/01.STR.29.9.1924","volume":"29","author":"M Zuccarello","year":"1998","unstructured":"Zuccarello M, Boccaletti R, Romano A, Rapoport RM. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 1998;29:1924\u20139.","journal-title":"Stroke"},{"key":"70_CR9","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0140-6736(89)92019-9","volume":"2","author":"H Masaoka","year":"1989","unstructured":"Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1989;2:1402.","journal-title":"Lancet"},{"key":"70_CR10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3171\/jns.2000.92.3.0390","volume":"92","author":"S. Juvela","year":"2000","unstructured":"Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000;92:390\u2013400.","journal-title":"J Neurosurg"},{"key":"70_CR11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3171\/jns.2002.97.6.1287","volume":"97","author":"S. Juvela","year":"2002","unstructured":"Juvela S. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;97:1287\u201393.","journal-title":"J Neurosurg"},{"key":"70_CR12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02576282","volume":"192","author":"H Ehrenreich","year":"1992","unstructured":"Ehrenreich H, Lange M, Near KA, et al. Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med (Berl) 1992;192:257\u201368.","journal-title":"Res Exp Med (Berl)"},{"key":"70_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3171\/jns.1995.82.1.0055","volume":"82","author":"V Seifert","year":"1995","unstructured":"Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995;82:55\u201362.","journal-title":"J Neurosurg"},{"key":"70_CR14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0090-3019(99)00179-2","volume":"53","author":"K Suzuki","year":"2000","unstructured":"Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000;53:131\u20135.","journal-title":"Surg Neurol"},{"key":"70_CR15","first-page":"819","volume":"25","author":"N Badjatia","year":"2004","unstructured":"Badjatia N, Topcuoglu MA, Pryor JC, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004;25:819\u201326.","journal-title":"AJNR Am J Neuroradiol"},{"key":"70_CR16","first-page":"81","volume":"42","author":"KF Lindegaard","year":"1988","unstructured":"Lindegaard KF, Nornes H, Bakke SJ, Sorteberg W, Nakstad P. Cerebral vasospasm after subarachnoid haemorrhage investigated by means of transcranial Doppler ultrasound. Acta Neurochir Suppl (Wien) 1988;42:81\u20134.","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"70_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/hs0102.100484","volume":"33","author":"JF Soustiel","year":"2002","unstructured":"Soustiel JF, Shik V, Shreiber R, Tavor Y, Goldsher D. Basilar vasospasm diagnosis: investigation of a modified \u201cLindegaard Index\u201d based on imaging studies and blood velocity measurements of the basilar artery. Stroke 2002;33:72\u20137.","journal-title":"Stroke"},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.1968.28.1.0014","volume":"28","author":"WE Hunt","year":"1968","unstructured":"Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968;28:14\u201320.","journal-title":"J Neurosurg"},{"key":"70_CR19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998;338:784\u201390.","journal-title":"N Engl J Med"},{"key":"70_CR20","first-page":"228","volume":"270","author":"M Clozel","year":"1994","unstructured":"Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3171\/jns.1996.84.3.0503","volume":"84","author":"M Zuccarello","year":"1996","unstructured":"Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H, Rapoport RM. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996;84:503\u20137.","journal-title":"J Neurosurg"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00006123-199601000-00028","volume":"38","author":"M Zimmermann","year":"1996","unstructured":"Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47\u20130203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 1996;38:115\u201320.","journal-title":"Neurosurgery"},{"key":"70_CR23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1227\/00006123-199507000-00012","volume":"37","author":"S Roux","year":"1995","unstructured":"Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995;37:78\u201385; discussion 85\u20136.","journal-title":"Neurosurgery"},{"key":"70_CR24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1227\/00006123-199507000-00013","volume":"37","author":"T Shigeno","year":"1995","unstructured":"Shigeno T, Clozel M, Sakai S, Saito A, Goto K. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 1995;37:87\u201390; discussion 90\u20131.","journal-title":"Neurosurgery"},{"key":"70_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00006123-199707000-00028","volume":"41","author":"M. Zimmermann","year":"1997","unstructured":"Zimmermann M. Endothelin in cerebral vasospasm. Clinical and experimental results. J Neurosurg Sci 1997;41:139\u201351.","journal-title":"J Neurosurg Sci"},{"key":"70_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3171\/jns.1995.83.3.0503","volume":"83","author":"A Hino","year":"1995","unstructured":"Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J Neurosurg 1995;83:503\u20139.","journal-title":"J Neurosurg"},{"key":"70_CR27","unstructured":"Wallnofer A, Grosset D, Ohman J, Zubkov Y, Mendelow A, Jones R, Teasdale G. Effects of the endothelin antagonist bosentan in patients with elevated Doppler velocities after aneurysmal SAH. In: Proceedings of the 6th International Conference on Cerebral Vasospasm; May 1997: Session 16:99\u2013100."},{"key":"70_CR28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3171\/jns.2000.93.6.0992","volume":"93","author":"MD Shaw","year":"2000","unstructured":"Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK\/Netherlands\/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000;93:992\u20137.","journal-title":"J Neurosurg"},{"key":"70_CR29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3171\/jns.2005.103.1.0009","volume":"103","author":"P Vajkoczy","year":"2005","unstructured":"Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005;103:9\u201317.","journal-title":"J Neurosurg"},{"key":"70_CR30","unstructured":"Macdonald RL, Kassell N, Mayer S, Schmiedek P, Weidauer S, Pasqualin A. Randomized trial of clazosentan for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. In: International Stroke Conference; 2007. San Francisco, CA."},{"key":"70_CR31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/00003246-200004000-00012","volume":"28","author":"AI Qureshi","year":"2000","unstructured":"Qureshi AI, Sung GY, Razumovsky AY, Lane K, Straw RN, Ulatowski JA. Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. Crit Care Med 2000;28:984\u201390.","journal-title":"Crit Care Med"},{"key":"70_CR32","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1378\/chest.121.6.1860","volume":"121","author":"RJ Barst","year":"2002","unstructured":"Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860\u20138.","journal-title":"Chest"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0022-3565(24)37130-7","volume":"283","author":"S Roux","year":"1997","unstructured":"Roux S, Breu V, Giller T, et al. Ro 61\u20131790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997;283:1110\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"70_CR34","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(94)90167-8","volume":"259","author":"M Zuccarello","year":"1994","unstructured":"Zuccarello M, Lewis AI, Rapoport RM. Endothelin ETA and ETB receptors in subarachnoid hemorrhage-induced cerebral vasospasm. Eur J Pharmacol 1994;259:R1\u20132.","journal-title":"Eur J Pharmacol"},{"key":"70_CR35","first-page":"1188","volume":"52","author":"J Hansen-Schwartz","year":"2003","unstructured":"Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L. Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries. Neurosurgery 2003;52:1188\u201394; 1194\u20135.","journal-title":"Neurosurgery"},{"key":"70_CR36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02688690220131750","volume":"16","author":"J Hansen-Schwartz","year":"2002","unstructured":"Hansen-Schwartz J, Szok D, Edvinsson L. Expression of ET(A) and ET(B) receptor mRNA in human cerebral arteries. Br J Neurosurg 2002;16:149\u201353.","journal-title":"Br J Neurosurg"},{"key":"70_CR37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.CIR.89.3.1203","volume":"89","author":"B Seo","year":"1994","unstructured":"Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203\u20138.","journal-title":"Circulation"},{"key":"70_CR38","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.bjp.0701036","volume":"120","author":"EJ Mickley","year":"1997","unstructured":"Mickley EJ, Gray GA, Webb DJ. Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol 1997;120:1376\u201382.","journal-title":"Br J Pharmacol"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-007-0070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12028-007-0070-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-007-0070-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:19:53Z","timestamp":1737443993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12028-007-0070-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,28]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,11,15]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s12028-007-0070-4","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"type":"print","value":"1541-6933"},{"type":"electronic","value":"1556-0961"}],"subject":[],"published":{"date-parts":[[2007,9,28]]}}}